Trial Profile
Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Apr 2020
Price :
$35
*
At a glance
- Drugs Sodium oligomannurarate (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Green Valley Pharmaceutical
- 27 Apr 2020 According to a Shanghai Green Valley Pharmaceutical media release, the NDA approval by the China NMPA, was based on the full data package of GV-971 nonclinical, clinical, chemistry, manufacturing and control (CMC), and the China Phase III clinical efficacy and safety outcomes (NCT02293915).
- 02 Nov 2019 According to a Shanghai Green Valley Pharmaceutical media release, the Chinas National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of mild to moderate Alzheimer's disease (AD) and improving cognitive function.
- 02 Nov 2019 According to a Shanghai Green Valley Pharmaceutical media release, this trial was led by the Mental Health Center affiliated to Shanghai Jiao Tong University School of Medicine and Peking Union Medical College Hospital.The entire clinical trial was managed by Ai Kunwei (formerly Kuntai).